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The answer depends on how headache is measured. The
question, however, is an important one. It is at the basis
of health policy, prioritisation and the due allocation of
health resources to headache care and the mitigation of
its clinical sequelae. From this perspective, prevalence
alone is not highly informative: it is the burdens arising
from headache disorders that dictate their impact on
public health. These burdens are multiple, diverse and
partly invisible [1]. Methods do not yet exist to measure
them all [1], but the focus meanwhile has been on dis-
ability. It is to this, primarily, that health, quality of life,
productivity and financial security are hostage.
So how much headache-related disability is there in
the world? Estimates of disability due to disease are a
principal objective of the Global Burden of Disease
(GBD) studies, performed reiteratively since 1990 and
described now as “the most comprehensive worldwide
observational epidemiological study to date” [2]. GBD
1990 was initiated by the World Bank and GBD 2000 by
the World Health Organization; subsequently, GBD has
been led by the Institute for Health Metrics and Evalu-
ation [3], and financially supported by the Bill and Me-
linda Gates Foundation. GBD uses a number of metrics:
among these, disability is measured in years lived with
disability (YLDs) and early mortality in years of life lost
(YLLs); disability-adjusted life years (DALYs) are the
summation of YLDs and YLLs. Migraine first featured in
GBD 2000 [4], and over 13 years ascended the ranks of
top causes of YLDs worldwide, from 19th in GBD 2000
[4] to seventh in GBD 2010 [5, 6] and sixth in GBD* Correspondence: t.steiner@imperial.ac.uk
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of public-health importance, tension-type headache
(TTH) was introduced in GBD 2010 [5] and medication-
overuse headache (MOH) in GBD 2013 (and ranked 18th
highest cause of YLDs) [7]. GBD 2013 established head-
ache disorders collectively as the third highest cause of
YLDs [8].
The rise of migraine over these years is not indicative
of increasing prevalence. While GBD is dependent on
data from the entire world, headache epidemiology is a
still-developing science [9]. Very large knowledge gaps
existed in 2000, particularly in regions outside the
Americas and Western Europe [10]. Filling these gaps
became the first priority of the Global Campaign against
Headache after its launch in 2004 [11–13]. Collaborating
in all subsequent GBD studies, the Global Campaign has
informed them by conducting new population-based
surveys in Georgia, Russia, China, Nepal, South India,
Saudi Arabia, Pakistan, Zambia, Ethiopia and Morocco
[14]. This concerted data-collection effort has allowed
much better estimates from GBD 2010 onwards. With
empirical data replacing many of the assumptions under-
lying the earlier GBD estimates, and an approach to
YLD calculation based on prevalence rather than inci-
dence and duration as in GBD 2000, estimates became
possible by country rather than by large world regions.
GBD 2015 has now been published [15, 16]. In this
latest iteration, a more systematic hierarchy has been
adopted in the grouping of related causes of DALYs.
Non-communicable disorders, at level 1, include neuro-
logical disorders at level 2; within the latter reside the
individual headache disorders (migraine, TTH and
MOH) at both levels 3 and 4. Future iterations of GBD
may more logically group the headache disorders to-
gether at level 3, as we have done in the following
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other neurological disorders combined (including de-
mentias), despite having no association with mortality
[16]. Because of this latter fact, the comparative impact of
headache disorders on public health is better indicated by
YLDs, taking disability but not mortality into account. At
level 3, headache disorders occupy sixth place among the
leading causes of disability, varying between 3rd and 7th in
regions around the world [15] (Table 1). While this demo-
tion by three places compared with GBD 2013 [8] may ap-
pear as a diminution, this is not so: successive iterations of
GBD, increasingly better informed, have shown total YLDs
attributed to headache disorders rising consistently. Ra-
ther, at level 3, headache disorders are displaced by
GBD 2015 groupings of low back and neck pain,
which clearly takes top place, sense organ diseases in
second place and skin diseases in fifth [15].
At level 4, migraine on its own is the 21st leading
cause of DALYs worldwide, tenth in Western Europe
and sixth worldwide in the age group 25–39 years [16].
Migraine, TTH and MOH are all diseases mainly affect-
ing young adults: in terms of YLDs, they remain collect-
ively in third place among level-3 causes in both males
and females aged 15–49 years [15] (Table 1). This is due
largely to migraine, which on its own, at level 4, is third
in this age group in both genders (Table 2). In present
estimates, migraine, estimated to affect 959 million
people worldwide, emerges by a long distance as theTable 1 Years lived with disability (YLDs) attributed to all headache
Region Gender Age ra
Global Both All
15–49
50–69
M All
15–49
50–69
F All
15–49
50–69
Western Europe Both All
Central and Eastern Europe and Central Asia
North Africa and Middle East
South Asia
SE and East Asia and Oceania
High-income Asia Pacific
High-income North America
Latin America and Caribbean
Sub-Saharan Africa
aMigraine, tension-type headache and medication-overuse headache
bamong the top level-3 causes of disability in GBD 2015most disabling headache disorder at population level
[15]. TTH, despite being the second most prevalent dis-
order in the world (behind dental caries) [7], adds much
less to population disability estimates because a low dis-
ability weight of 0.036 (on a scale of 0–1) is accorded to
the headache of TTH compared with 0.434 for the ictal
state of migraine [17]. MOH is recognised as far more
disabling at an individual level but, with its prevalence
still very poorly estimated in many regions [18, 19], it
stays ranked as 18th cause of YLDs in GBD 2015 [15].
There can be no doubt that migraine is a major con-
tributor to public ill health in all countries, climes and cul-
tures. Table 2 shows it consistently ranked fifth to eighth
among the top causes of disability in all world regions.
Further, the notion that migraine is a disease preferentially
affecting rich industrialised nations is dispelled by the
comparison in Table 2 between low- and high-income
countries. It is worth adding here that GBD currently con-
siders only the disability burden associated with the ictal
state of headache disorders, whereas there is evidence of
interictal burden in a considerable proportion of people
with migraine and in a small proportion of people with
TTH [20]. The significance of interictal burden is that, al-
though it may be at relatively low level, it is present for
longer periods of time than ictal burden. With new data
indicating that interictal disability in headache disorders is
real and measurable [20], future iterations of GBD should
consider adding this component of disability.disordersa by gender, age and world region
nge (years) YLDs per 100,000 % of total Rankb
601 5.61 6
813 8.13 3
732 4.67 6
438 4.35 7
597 6.49 3
516 3.25 6
767 6.76 5
1,036 9.59 3
940 5.58 6
783 6.32 4
778 6.41 4
702 6.80 3
730 6.55 5
443 4.48 7
607 5.34 5
646 5.01 6
688 6.76 4
449 4.27 6
Table 2 Years lived with disability (YLDs) attributed to migraine by gender, age, world region and country income
Region Gender Age range (years) YLDs per 100,000 % of total Ranka
Global Both All 446 4.17 7
15–49 615 6.16 3
50–69 495 3.03 8
M All 311 3.09 8
15–49 432 4.70 3
50–69 324 2.05 13
F All 584 5.15 4
15–49 805 7.46 3
50–69 659 3.91 7
Western Europe Both All 580 4.69 5
Central and Eastern Europe and Central Asia 515 4.25 6
North Africa and Middle East 498 4.83 5
South Asia 569 5.11 5
SE and East Asia and Oceania 334 3.39 8
High-income Asia Pacific 434 3.82 5
High-income North America 473 3.68 8
Latin America and Caribbean 497 4.89 7
Sub-Saharan Africa 312 3.12 6
All low-income countries Both All 314 3.18 6
M 227 2.41 8
F 400 3.88 5
All high-income countries Both All 502 4.09 6
M 296 2.62 7
F 700 5.31 4
aamong the top level-4 causes of disability in GBD 2015
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ache disorders together at level 3, they might consider
including neck pain in this grouping rather than with
low back pain: the last is markedly different from neck
pain not only in its clinical sequelae but also aetiologically,
whereas how much neck pain is actually secondary to
headache? Meanwhile it is still not known how much
headache – or headache-related disability – there is in the
world. There are still large data gaps to be filled, particu-
larly with regard to MOH, which only recently has been
included as a separate entity in population-based studies
[18, 19]. The Global Campaign has further studies under-
way or planned: in Guatemala, Peru, Nigeria, Uganda,
Kuwait, North India, Sri Lanka and Mongolia [14]. GBD
estimates of global averages properly take into account all
available data, but published surveys are up to 30 years
old, and use a variety of ascertainment methods [10].
Crude adjustments are relied upon to correct for measure-
ment biases arising from less than ideal study methods or
questionable case definitions. Global Campaign studies
use standardised and higher quality methodology [9].
With the single exception of China, all of them so farperformed have produced national estimates greater than
GBD’s mean global estimates [6, 8]. As the new studies
continue to feed data into future iterations of GBD, it is
inevitable that the proportion of global disability correctly
attributed to headache will continue to rise.
The importance of this measure is that it serves as a
needs assessment, marking the existence of a very large
burden of ill health to inform health policy in countries
and regions the world over. GBD measures disease bur-
den as it is – alleviated by whatever treatments are made
available. The persistence of this heavy headache burden
is a clear signal of continuing health-care failures that
must be addressed [21, 22].Authors’ contribution
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